Evidence map›Paper›PMID 34953934›Full record

ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2022

Longitudinal patient-reported outcomes and survival among early-stage non-small cell lung cancer patients receiving stereotactic body radiotherapy.

Kea Turner, Naomi C Brownstein, Zachary Thompson, Issam El Naqa, Yi Luo, Heather S L Jim, Dana E Rollison, Rachel Howard, Desmond Zeng, Stephen A Rosenberg and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Patient-Reported Outcomes as Interradiographic Predictors of Response in Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kea TurnerDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, USA. Electronic address: kea.turner@moffitt.org.
Naomi C BrownsteinDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, USA. Electronic address: Naomi.Brownstein@moffitt.org.
Zachary ThompsonDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, USA. Electronic address: Zachary.Thompson@moffitt.org.
Issam El NaqaDepartment of Machine Learning, Moffitt Cancer Center, USA. Electronic address: Issam.ElNaqa@moffitt.org.
Yi LuoDepartment of Machine Learning, Moffitt Cancer Center, USA. Electronic address: Yi.Luo@moffitt.org.
Heather S L JimDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, USA. Electronic address: Heather.Jim@moffitt.org.
Dana E RollisonDepartment of Cancer Epidemiology, Moffitt Cancer Center, USA. Electronic address: Dana.Rollison@moffitt.org.
Rachel HowardDepartment of Health Informatics, Moffitt Cancer Center, USA. Electronic address: Rachel.Howard@moffitt.org.
Desmond ZengMorsani College of Medicine, University of South Florida, USA. Electronic address: zengd@usf.edu.
Stephen A RosenbergDepartment of Radiation Oncology, Moffitt Cancer Center, USA; Department of Thoracic Oncology, Moffitt Cancer Center, USA. Electronic address: Stephen.Rosenberg@moffitt.org.
Bradford PerezDepartment of Radiation Oncology, Moffitt Cancer Center, USA; Department of Thoracic Oncology, Moffitt Cancer Center, USA. Electronic address: Bradford.Perez@moffitt.org.
Andreas SaltosDepartment of Thoracic Oncology, Moffitt Cancer Center, USA. Electronic address: Andreas.Saltos@moffitt.org.
Laura B OswaldDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, USA. Electronic address: Laura.Oswald@moffitt.org.
Brian D GonzalezDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, USA. Electronic address: Brian.Gonzalez@moffitt.org.
Jessica Y IslamDepartment of Cancer Epidemiology, Moffitt Cancer Center, USA. Electronic address: Jessica.Islam@moffitt.org.
Amir Alishahi TabrizDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, USA. Electronic address: Amir.Alishahi@moffitt.org.
Wenbin ZhangDepartment of Machine Learning, Gates Hillman Center, Carnegie Mellon University, USA. Electronic address: wenbinzhang@cmu.edu.
Thomas J DillingDepartment of Radiation Oncology, Moffitt Cancer Center, USA; Department of Thoracic Oncology, Moffitt Cancer Center, USA. Electronic address: Thomas.Dilling@moffitt.org.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

background and purposeThe study objective was to determine whether longitudinal changes in patient-reported outcomes (PROs) were associated with survival among early-stage, non-small cell lung cancer (NSCLC) patients undergoing stereotactic body radiation therapy (SBRT). MATERIALS AND

methodsData were obtained from January 2015 through March 2020. We ran a joint probability model to assess the relationship between time-to-death, and longitudinal PRO measurements. PROs were measured through the Edmonton Symptom Assessment Scale (ESAS). We controlled for other covariates likely to affect symptom burden and survival including stage, tumor diameter, comorbidities, gender, race/ethnicity, relationship status, age, and smoking status.

resultsThe sample included 510 early-stage NSCLC patients undergoing SBRT. The median age was 73.8 (range: 46.3-94.6). The survival component of the joint model demonstrates that longitudinal changes in ESAS scores are significantly associated with worse survival (HR: 1.04; 95% CI: 1.02-1.05). This finding suggests a one-unit increase in ESAS score increased probability of death by 4%. Other factors significantly associated with worse survival included older age (HR: 1.04; 95% CI: 1.03-1.05), larger tumor diameter (HR: 1.21; 95% CI: 1.01-1.46), male gender (HR: 1.87; 95% CI: 1.36-2.57), and current smoking status (HR: 2.39; 95% CI: 1.25-4.56).

conclusionPROs are increasingly being collected as a part of routine care delivery to improve symptom management. Healthcare systems can integrate these data with other real-world data to predict patient outcomes, such as survival. Capturing longitudinal PROs-in addition to PROs at diagnosis-may add prognostic value for estimating survival among early-stage NSCLC patients undergoing SBRT.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsRadiosurgerySmall Cell Lung CarcinomaAgedHumansMaleNeoplasm StagingPatient Reported Outcome MeasuresRetrospective StudiesTreatment OutcomeLung cancerNon small cellPatient reported outcomesSBRT

Identifiers

PMID34953934
PMCPMC8934278

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.